ReviewInternational journal of molecular sciences2024
Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Essential Oil Profiles of Lippia turbinata (Verbenaceae) from Argentina: Insights from a Systematic Review and Meta-Analysis.ChemistryOpen · 2025Pooled it
- Terpesomes as Advanced Nanocarriers for Enhanced Drug Delivery: Formulation Strategies, Mechanistic Insights, and Therapeutic Applications.AAPS PharmSciTech · 2026Review
- Baihe Dihuang decoction activates cannabinoid type 2 receptor to regulate microglial polarization and alleviate anxiety-like behavior in chronic restraint stress mice.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Article
- Beta-Caryophyllene Prevents Ouabain-Induced Neurodegeneration and Behavioral Alterations Through PKA/GSK-3β Pathway.Neurochemical research · 2026Article
- Assessment of the Acute Toxicity and Anxiolytic-Like Effect of α-Humulene in Adult Zebrafish (Danio rerio).Chemistry & biodiversity · 2026Article
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
- Neuropharmacological Validation ofPlants (Basel, Switzerland) · 2026Article
- Modulation of monoaminergic neurotransmission in substance use disorders: a neuropharmacological perspective focusing on plant-derived metabolites.Frontiers in pharmacology · 2026Review
- A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Toward a Cannabis Terroir: Untargeted Metabolomic Profiling of Authentic Samples Using Gas Chromatography-High-Resolution Mass Spectrometry (GC-HRMS) and Liquid Chromatography-High-Resolution Tandem Mass Spectrometry (LC-HRMS/MS).Drug testing and analysis · 2025Article
- Article
- Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Process Development for GMP-Grade Full Extract Cannabis Oil: Towards Standardized Medicinal Use.Pharmaceutics · 2025Article
- ADME/Tox study and the effect of β-Caryophyllene on the resistant strain ofToxicology reports · 2025Article
- The Role of Endocannabinoids in Physiological Processes and Disease Pathology: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Metabolomic Characterization and Bioinformatic Studies of Bioactive Compounds in Two Varieties ofInternational journal of molecular sciences · 2025Article
- Ameliorative Role of β-Caryophyllene on Antioxidant Biomarkers in a Paroxetine-Induced Model of Male Sexual Dysfunction.Basic & clinical pharmacology & toxicology · 2025Article
- Article
- Chemical Characterization and Antibiotic-Enhancing Activity of the Essential Oils of Propolis ofPlants (Basel, Switzerland) · 2025Article
- 3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract.Gels (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mental disorders account for one of the most prevalent categories of the burden of disease worldwide, with depression expected to be the largest contributor by 2030, closely followed by anxiety. The COVID-19 pandemic possibly exacerbated these challenges, especially amongst adolescents, who experienced isolation, disrupted routines, and limited healthcare access. Notably, the pandemic has been associated with long-term neurological effects known as "long-COVID", characterized by both cognitive and psychopathological symptoms. In general, psychiatric disorders, including those related to long-COVID, are supposed to be due to widespread inflammation leading to neuroinflammation. Recently, the endocannabinoid system (ECS) emerged as a potential target for addressing depression and anxiety pathophysiology. Specifically, natural or synthetic cannabinoids, able to selectively interact with cannabinoid type-2 receptor (CB2R), recently revealed new therapeutic potential in neuropsychiatric disorders with limited or absent psychotropic activity. Among the most promising natural CB2R ligands, the bicyclic sesquiterpene β-caryophyllene (BCP) has emerged as an excellent anti-inflammatory and antioxidant therapeutic agent. This review underscores BCP's immunomodulatory and anti-inflammatory properties, highlighting its therapeutic potential for the management of depression and anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.